Tag Archives: oncology

Basilea announced improved operating results in its H1-2013 financials

Posted on 22, August 2013 by EuropaWire PR Editors

Continued improvement in financial performance Cash and short-term investments of CHF 262.8 million Guidance on isavuconazole phase 3 topline data and ceftobiprole regulatory decision in Europe maintained for H2 2013 Significant agreement with BARDA of up to USD 89 million … Read the full press release →

Posted in Business, Financial, Healthcare, Investment, Pharma & Biotech, Switzerland

Tagged antibiotic BAL30072, bacterial infections, BAL101553, BAL30072, Barbara Zink PhD MBA, BARDA, Basel, Basilea Pharmaceutica Ltd, Basilea Pharmaceutica Ltd. conference call, Ceftobiprole, ceftobiprole regulatory decision, fungal infections, Isavuconazole, isavuconazole phase 3 topline data, oncology, oral alitretinoin, Peer Nils Schröder PhD, SIX: BSLN, Toctino®

AstraZeneca, University of Cambridge and Cancer Research UK partner on 3 pre-clinical and clinical oncology projects

Posted on 16, July 2013 by EuropaWire PR Editors

16-7-2013 — /europawire.eu/ — AstraZeneca today announced that it has entered into an agreement with the University of Cambridge and Cancer Research UK for a two-year collaboration on three pre-clinical and clinical oncology projects. This agreement with world-leading medical research institutions … Read the full press release →

Posted in Business, Education, Healthcare, Pharma & Biotech, Science, United Kingdom

Tagged AstraZeneca, Babraham Institute, Cambridge University Hospitals, Cancer, cancer research, Cancer Research UK, cancers, collaboration, David Neal, medical research, Olaparib, oncology, oncology projects, pancreatic, prostate, selumetinib, Susan Galbraith, tumour mutations, University of Cambridge

SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® results announced by AstraZeneca and Bristol-Myers Squibb

Posted on 20, June 2013 by EuropaWire PR Editors

20-6-2013 — /europawire.eu/ — AstraZeneca and Bristol-Myers Squibb announced today top-line results of the Phase IV SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin). In this study of adult patients with … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Science, United Kingdom

Tagged anti-diabetic therapies, AstraZeneca, autoimmune, biopharmaceutical, biopharmaceutical business, Bristol-Myers Squibb, cardiovascular, cardiovascular death, cardiovascular disease, clinical trial, Diabetes Mellitus, Hadassah University Medical Center, infection, inflammation, metabolic, neuroscience diseases, non-fatal ischaemic stroke, non-fatal myocardial infarction, oncology, Onglyza, prescription medicines, respiratory, SAVOR-TIMI-53, saxagliptin, TIMI Study Group, type 2 diabetes